rs533875300

Variant summary

Our verdict is Benign. The variant received -11 ACMG points: 1P and 12B. PM4_SupportingBP6_Very_StrongBS2

The NM_001429.4(EP300):​c.6798_6800delGCA​(p.Gln2267del) variant causes a disruptive inframe deletion change. The variant allele was found at a frequency of 0.00378 in 1,613,788 control chromosomes in the GnomAD database, including 15 homozygotes. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0023 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0039 ( 15 hom. )

Consequence

EP300
NM_001429.4 disruptive_inframe_deletion

Scores

Not classified

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts P:1B:11O:1

Conservation

PhyloP100: 6.12

Publications

5 publications found
Variant links:
Genes affected
EP300 (HGNC:3373): (E1A binding protein p300) This gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It functions as histone acetyltransferase that regulates transcription via chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Defects in this gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. [provided by RefSeq, Jul 2008]
EP300-AS1 (HGNC:50504): (EP300 antisense RNA 1)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -11 ACMG points.

PM4
Nonframeshift variant in NON repetitive region in NM_001429.4. Strenght limited to Supporting due to length of the change: 1aa.
BP6
Variant 22-41178506-TCAG-T is Benign according to our data. Variant chr22-41178506-TCAG-T is described in CliVar as Benign/Likely_benign. Clinvar id is 341826.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-41178506-TCAG-T is described in CliVar as Benign/Likely_benign. Clinvar id is 341826.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-41178506-TCAG-T is described in CliVar as Benign/Likely_benign. Clinvar id is 341826.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-41178506-TCAG-T is described in CliVar as Benign/Likely_benign. Clinvar id is 341826.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-41178506-TCAG-T is described in CliVar as Benign/Likely_benign. Clinvar id is 341826.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-41178506-TCAG-T is described in CliVar as Benign/Likely_benign. Clinvar id is 341826.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-41178506-TCAG-T is described in CliVar as Benign/Likely_benign. Clinvar id is 341826.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-41178506-TCAG-T is described in CliVar as Benign/Likely_benign. Clinvar id is 341826.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS2
High AC in GnomAd4 at 343 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
EP300NM_001429.4 linkc.6798_6800delGCA p.Gln2267del disruptive_inframe_deletion Exon 31 of 31 ENST00000263253.9 NP_001420.2 Q09472Q7Z6C1
EP300NM_001362843.2 linkc.6720_6722delGCA p.Gln2241del disruptive_inframe_deletion Exon 30 of 30 NP_001349772.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
EP300ENST00000263253.9 linkc.6798_6800delGCA p.Gln2267del disruptive_inframe_deletion Exon 31 of 31 1 NM_001429.4 ENSP00000263253.7 Q09472

Frequencies

GnomAD3 genomes
AF:
0.00226
AC:
343
AN:
151800
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000920
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00216
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000208
Gnomad FIN
AF:
0.0000945
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00392
Gnomad OTH
AF:
0.00192
GnomAD2 exomes
AF:
0.00186
AC:
467
AN:
251286
AF XY:
0.00179
show subpopulations
Gnomad AFR exome
AF:
0.000923
Gnomad AMR exome
AF:
0.00139
Gnomad ASJ exome
AF:
0.0000994
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000139
Gnomad NFE exome
AF:
0.00331
Gnomad OTH exome
AF:
0.00163
GnomAD4 exome
AF:
0.00394
AC:
5753
AN:
1461868
Hom.:
15
AF XY:
0.00378
AC XY:
2752
AN XY:
727232
show subpopulations
African (AFR)
AF:
0.000538
AC:
18
AN:
33480
American (AMR)
AF:
0.00159
AC:
71
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.0000765
AC:
2
AN:
26136
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39700
South Asian (SAS)
AF:
0.000591
AC:
51
AN:
86258
European-Finnish (FIN)
AF:
0.000169
AC:
9
AN:
53402
Middle Eastern (MID)
AF:
0.000520
AC:
3
AN:
5768
European-Non Finnish (NFE)
AF:
0.00484
AC:
5380
AN:
1112004
Other (OTH)
AF:
0.00361
AC:
218
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.477
Heterozygous variant carriers
0
406
812
1219
1625
2031
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
232
464
696
928
1160
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00226
AC:
343
AN:
151920
Hom.:
0
Cov.:
32
AF XY:
0.00199
AC XY:
148
AN XY:
74268
show subpopulations
African (AFR)
AF:
0.000917
AC:
38
AN:
41432
American (AMR)
AF:
0.00216
AC:
33
AN:
15264
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5136
South Asian (SAS)
AF:
0.000208
AC:
1
AN:
4808
European-Finnish (FIN)
AF:
0.0000945
AC:
1
AN:
10578
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00392
AC:
266
AN:
67922
Other (OTH)
AF:
0.00190
AC:
4
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.488
Heterozygous variant carriers
0
17
34
50
67
84
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00268
Hom.:
0
Bravo
AF:
0.00227
EpiCase
AF:
0.00398
EpiControl
AF:
0.00362

ClinVar

Significance: Benign/Likely benign
Submissions summary: Pathogenic:1Benign:11Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:5
-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Aug 24, 2017
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Nov 06, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 24728327, 27416986, 26960974) -

Mar 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

EP300: PM4:Supporting, BS1, BS2 -

Rubinstein-Taybi syndrome due to EP300 haploinsufficiency Pathogenic:1Benign:2
May 04, 2023
Molecular Genetics, Royal Melbourne Hospital
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

European Non-Finnish population allele frequency is 0.3034% (rs533875300, 430/128992 alleles, 0 homozygotes in gnomAD v2.1). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.4.0, this variant is classified as LIKELY BENIGN. Following criteria are met: BS1 -

Nov 05, 2019
Wessex Regional Genetics Laboratory, Salisbury District Hospital
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 13, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Rubinstein-Taybi syndrome due to CREBBP mutations Benign:2
May 28, 2019
Mendelics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1Other:1
Sep 19, 2013
ITMI
Significance:not provided
Review Status:no classification provided
Collection Method:reference population

- -

Nov 08, 2016
Eurofins Ntd Llc (ga)
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

EP300-related disorder Benign:1
May 15, 2019
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
PhyloP100
6.1
Mutation Taster
=78/22
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs533875300; hg19: chr22-41574510; COSMIC: COSV54325791; COSMIC: COSV54325791; API